Могут ли препараты ГПП-1 защитить ваше сердце? Кардиолог разбирает данные

In this video, interventional cardiologist Dr. Phil Dattilo breaks down the expanding clinical data connecting GLP-1 and GIP/GLP-1 receptor agonist medications to cardiovascular health. From major adverse cardiovascular events (MACE) and heart failure with preserved ejection fraction (HFpEF) to reductions in inflammation (CRP) and overall metabolic health, we look closely at what the landmark clinical trials actually show. Selected clinical trials: SELECT: https://doi.org/10.1056/NEJMoa2307563 FLOW: https://doi.org/10.1056/NEJMoa2403347 SOUL: https://doi.org/10.1056/NEJMoa2501006 SURPASS-CVOT: https://doi.org/10.1056/NEJMoa2505928 STEP-HFpEF: https://doi.org/10.1056/NEJMoa2306963 SUMMIT: https://doi.org/10.1056/NEJMoa2410027 About Dr. Dattilo Phil Dattilo, MD, is a board-certified interventional cardiologist with an interest in preventive cardiovascular medicine, coronary artery disease and cardiovascular risk reduction. This video is for educational purposes and does not constitute individualized medical advice. The benefits and risks of GLP-1–based treatment depend on the medication, clinical indication and individual patient. #Cardiology #GLP1 #HeartHealth #PreventativeMedicine #MedicalEducation #HealthScience